ADMA Biologics Balance Sheet Health
Financial Health criteria checks 6/6
ADMA Biologics has a total shareholder equity of $188.3M and total debt of $131.1M, which brings its debt-to-equity ratio to 69.6%. Its total assets and total liabilities are $376.4M and $188.1M respectively. ADMA Biologics's EBIT is $86.7M making its interest coverage ratio 4.7. It has cash and short-term investments of $88.2M.
Key information
69.6%
Debt to equity ratio
US$131.07m
Debt
| Interest coverage ratio | 4.7x |
| Cash | US$88.24m |
| Equity | US$188.27m |
| Total liabilities | US$188.13m |
| Total assets | US$376.40m |
Recent financial health updates
Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Dec 02Recent updates
ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price
Sep 06ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality
Aug 16ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Jul 27ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 24Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
May 30ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
Aug 21ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M
Aug 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics: A Path To Profits Looks Clear
May 12ADMA: Pertinent Updates
Apr 18ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Mar 29ADMA Biologics: 2021 Was Tough
Jan 18ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Dec 02ADMA Biologics: Turning A Corner
Nov 20Financial Position Analysis
Short Term Liabilities: ADMA's short term assets ($303.7M) exceed its short term liabilities ($44.2M).
Long Term Liabilities: ADMA's short term assets ($303.7M) exceed its long term liabilities ($144.0M).
Debt to Equity History and Analysis
Debt Level: ADMA's net debt to equity ratio (22.7%) is considered satisfactory.
Reducing Debt: ADMA's debt to equity ratio has reduced from 175.6% to 69.6% over the past 5 years.
Debt Coverage: ADMA's debt is well covered by operating cash flow (55.7%).
Interest Coverage: ADMA's interest payments on its debt are well covered by EBIT (4.7x coverage).